Recently, Fuji film Group company Toyama Chemical Co. Ltd signed a licensing agreement with TR- Pharm, a Turkey based company. The agreement aims at developing, manufacturing and marketing pharmaceuticals, concerning Toyama Chemical's rheumatoid arthritis drug "iguratimod".
Iguratimod is a drug for treating rheumatoid arthritis, jointly developed with Eisai Co., Ltd. It was approved for manufacturing and marketing in Japan on June 29, 2012, and launched in the domestic market in September 2015.
Iguratimod is an oral drug that underwent domestic clinical trials in combination with methotrexate, the standard care for rheumatoid arthritis, and became the first agent in Japan that demonstrated efficacy when administered in combination with MTX on rheumatoid arthritis patients. Iguratimod is a drug that provides a new treatment option for rheumatoid arthritis.
Under the licensing agreement, Toyama Chemical provides TR-Pharm with the exclusive rights for developing, manufacturing and marketing iguratimod for the treatment of rheumatoid arthritis in Turkey, Middle East and North Africa, in exchange for a lump-sum payment and royalty. Toyama Chemical, a subsidiary of Fujifilm holdings Corporation, specializes in pharmaceutical research and development, and strives to contribute to further development of global health care through new drug development.